Skip to content

Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?

Search Clinical Trials

Trial Objectives


The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

Who Can Participate


You may be able to join this study if you are at least 18 years old, with medically inoperable Stage I/IIA NSCLC and if you have not received prior anticancer therapy for lung cancer.

Age: 18+ Gender Any

Estimated Time Commitment


Up to 7 years

Time Commitment Details


If you are eligible and choose to be in the study, your participation will last up to 7 years. You will be asked to visit the study site about 26 times.

Payment & Reimbursement


Payment Not Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Jami Henriksen
303.398.1233

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Merck Sharp & Dohme Corp.

Principal Investigators

Laurie L. Carr

Laurie L. Carr, MD

Co-Investigators

Jeffrey Kern

Jeffrey Kern, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required